NASDAQ · RLYB
Rallybio Corporation
$15.41-$0.58 (-3.63%)
Rallybio Corporation’s quoted price sits in the upper half of its reported 52-week range, 12.31% below the high.
Loading market information…
NASDAQ · TAOX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
TAO Synergies Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.89% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
TAO Synergies Inc.’s next earnings report is currently expected on Dec 2, 2026, with estimated earnings per share of -$12.75. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow TAO Synergies Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
TAO Synergies Inc. operates as a biopharmaceutical company currently in the clinical development stage. It is dedicated to advancing a bryostatin-1 therapeutic platform, specifically designed to combat Alzheimer's and various other neurodegenerative and cognitive disorders. Beyond its drug development efforts, the firm is also diversifying its treasury strategy, with a new approach centered on the management of digital assets, primarily focusing on the acquisition and 'staking' of TAO cryptocurrency.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:02 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Mar 27, 2025 |
| -$4.18-102.91% vs estimate |
| $0.00 |
| Q3 2024 | Nov 12, 2024 | -$4.58-134.87% vs estimate | $0.00 |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$15.41-$0.58 (-3.63%)
Rallybio Corporation’s quoted price sits in the upper half of its reported 52-week range, 12.31% below the high.
$2.48-$0.02 (-0.8%)
Boundless Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.62% below the high.
$0.81+$0.01 (+1.17%)
iBio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.7% below the high.
$6.53+$0.19 (+2.92%)
NextCure, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.55% below the high.
$0.38-$0.03 (-7.1%)
Klotho Neurosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.26% below the high.
$3.87-$0.13 (-3.25%)
Plus Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 83.48% below the high.
$3.34-$0.04 (-1.09%)
Intensity Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 92.32% below the high.
$1.26-$1.84 (-59.35%)
Sonnet BioTherapeutics Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.47% below the high.
